# A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

> **NCT01733004** · PHASE1 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** MM-141

## Key facts

- **NCT ID:** NCT01733004
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2016-01
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2016-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733004, "A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01733004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*